# Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease

Study · id `cardio:ct-nct02231138` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02231138](<https://clinicaltrials.gov/study/NCT02231138>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02231138

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1600 participants.

## Technical summary

Registry record NCT02231138. Allocation not applicable; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2016-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1600 participants (planned count; ClinicalTrials.gov record NCT02231138, source copy `cardio:ctgov-nct02231138-2016-06-01`, retrieved 2026-10-26)
- Start date: 2014-09 (registry gives no type) (ClinicalTrials.gov record NCT02231138, source copy `cardio:ctgov-nct02231138-2016-06-01`, retrieved 2026-10-26)
- Primary completion: 2016-01 (actual) (ClinicalTrials.gov record NCT02231138, source copy `cardio:ctgov-nct02231138-2016-06-01`, retrieved 2026-10-26)
- Completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02231138, source copy `cardio:ctgov-nct02231138-2016-06-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02231138, source copy `cardio:ctgov-nct02231138-2016-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02231138-2016-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): Abelmoschus manihot (AM)
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER
- Collaborator: Jiangsu Suzhong Pharmaceutical Group Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

## Provenance

Content hash: 9ac705e6447d0930f264dd8bd970efa31529d232cd22e31524af33fda33d037e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
